Platelets in rheumatic diseases: Friend or foe?

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 552-566

  Gasparyan, Armen Yuri ^a   Ayvazyan, Lilit ^b   Pretorius, Etheresia ^c   Kitas, George D ^a,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antirheumatic drugs; Aspirin; Drug design; Inflammation; Platelet function; Rheumatic disease; Thrombosis; Vasculopathy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT;

ANGIOGENESIS; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTHRITIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CARTILAGE; COCHRANE LIBRARY; COHORT ANALYSIS; DENDRITIC CELL; ENDOTHELIAL DYSFUNCTION; GIANT CELL ARTERITIS; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; MEDLINE; MEGAKARYOPOIESIS; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SEROTONIN RELEASE; SKIN ULCER; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TARGET CELL DESTRUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TISSUE REPAIR;

ANIMALS; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RHEUMATIC DISEASES;

EID: 84894062712     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282004140213143843     Document Type: Review

References (175)

1. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008; 111(3): 981-6.
2. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17(1): 47-58.
3. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115(12): 3339-47.
4. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 Suppl 1: S13-33.
5. Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012; 23(7): 510-25.
6. Cloutier N, Paré A, Farndale RW, et al. Platelets can enhance vascular permeability. Blood 2012; 120(6): 1334-43.
7. Sarac H, Markeljevic J, Mokrovic G, Erdeljic V, Bozina N, Cicin-Sain L. Platelet serotonin in primary Sjögren's syndrome: level and relation with disease activity. J Neuroimmunol 2012; 251(1-2): 87-9.
8. Onat AM, Ozçakar L, Oztürk MA, et al. Plasma and platelet serotonin levels in familial Mediterranean fever. Clin Exp Rheumatol 2007; 25(4 Suppl 45): S16-20.
9. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12(5): 261-73.
10. Schmitt-Sody M, Metz P, Gottschalk O, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007; 18(5): 365-72.
11. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets 2008; 19(5): 317-21.
12. Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010; 21(5): 360-7.
13. Ioannou A, Kannan L, Tsokos GC. Platelets, complement and tissue inflammation. Autoimmunity 2013; 46(1): 1-5.
14. Shanker J, Gasparyan AY, Kitas GD, Kakkar VV. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms. Curr Vasc Pharmacol 2011; 9(4): 479-89.
15. Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18(33): 5379-91.
16. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011; 31(11): 1409-17.
17. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8(4): 437-49.
18. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369(9561): 587-96.
19. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36(6): 1195-9.
20. Pereira J, Alfaro G, Goycoolea M, et al. Circulating plateletderived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95(1): 94-9.
21. Sallai KK, Nagy E, Bodó I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36(3): 198-205.
22. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49(12): 2243-54.
23. Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45(7): 851-4.
24. Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98(2): 336-41.
25. Viallard JF, Pellegrin JL, Vergnes C, et al. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 1999; 105(2): 532-7.
26. Dorsch CA, Meyerhoff J. Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus. Arthritis Rheum 1982; 25(8): 966-73.
27. Averbuch M, Koifman B, Levo Y. Lupus anticoagulant, thrombosis and thrombocytopenia in systemic lupus erythematosus. Am J Med Sci 1987; 293(1): 2-5.
28. Hasselaar P, Derksen RH, Blokzijl L, et al. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989; 48(11): 933-40.
29. Escolar G, Font J, Reverter JC, et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb 1992; 12(2): 196-200.
30. Nojima J, Suehisa E, Kuratsune H, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus-possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999; 81(3): 436-41.
31. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and antiphosphatidylserine/ prothrombin antibodies-Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91(5): 967-76.
32. Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006; 54(2): 670-4.
33. Mehta N, Uchino K, Fakhran S, et al. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 2008; 39(12): 3236-41.
34. Peerschke EI, Yin W, Alpert DR, Roubey RA, Salmon JE, Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2009; 18(6): 530-8.
35. Musiał J. Antiphospholipid antibodies and thrombosis. Thromb Res 2012; 129(3): 345-7.
36. Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17(10): 888-94.
37. Avalos I, Tsokos GC. The role of complement in the antiphospholipid syndrome-associated pathology. Clin Rev Allergy Immunol 2009; 36(2-3): 141-4.
38. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376(9751): 1498-509.
39. Jy W, Tiede M, Bidot CJ, et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007; 121(3): 319-25.
40. Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun 2010; 35(3): 248-55.
41. Yonal I, Hindilerden F, Hancer VS, et al. The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res 2012; 129(4): 486-91.
42. Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22(4): 187-94.
43. Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP Syndrome and Its Relationship with Antiphospholipid Syndrome and Antiphospholipid Antibodies. Semin Arthritis Rheum 2011; 41(3): 517-23.
44. Tsirigotis P, Mantzios G, Pappa V, et al. Antiphospholipid syndrome: a predisposing factor for early onset HELLP syndrome. Rheumatol Int 2007; 28(2): 171-4.
45. Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology 2012; 17 Suppl 1: 153-5.
46. John H, Toms TE, Kitas GD. Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol 2011; 26(4): 327-33.
47. Miller AM, McInnes IB. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des 2011; 17(1): 1-8.
48. Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2012; 18(11): 1502-11.
49. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094-108.
50. Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 2010; 49(9): 1618-31.
51. Farr M, Wainwright A, Salmon M, Hollywell CA, Bacon PA. Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1984; 4(1): 13-7.
52. Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC, Soma P. Scanning electron microscopy of fibrin networks in rheumatoid arthritis: a qualitative analysis. Rheumatol Int 2012; 32(6): 1611-5.
53. Berckmans RJ, Nieuwland R, Tak PP, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002; 46(11): 2857-66.
54. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327(5965): 580-3.
55. Boilard E, Larabee K, Shnayder R, et al. Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol 2011; 186(7): 4361-6.
56. Mac Mullan PA, Peace AJ, Madigan AM, Tedesco AF, Kenny D, McCarthy GM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology (Oxford) 2010; 49(2): 240-5.
57. Farr M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983; 42(5): 545-9.
58. Ertenli I, Kiraz S, Oztürk MA, Haznedaroǧlu I, Celik I, Calgüneri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003; 23(2): 49-60.
59. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011; 31(2): 153-64.
60. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KM, Kitas GD. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 2010; 9(1): 45-50.
61. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369(9570): 1379-90.
62. van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 2012; 31(11): 1529-35.
63. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and metaanalysis. Arthritis Care Res (Hoboken) 2011; 63(4): 557-63.
64. Bergfeldt L, Edhag O, Holm G, Norberg R. Platelet aggregating activity in serum from patients with HLA-B27 associated rheumatic and cardiac disorders: a possible link to the proliferative vascular changes. Br Heart J 1991; 65(4): 184-7.
65. Wang F, Yan CG, Xiang HY, Xing T, Wang NS. The significance of platelet activation in ankylosing spondylitis. Clin Rheumatol 2008; 27(6): 767-9.
66. Yazici S, Yazici M, Erer B, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets 2010; 21(2): 126-31.
67. Nalbant S, Cagiltay E, Sahan B, Terekeci HM, Oktenli C. The vasoactive intestinal polypeptide (VIP) levels at the patients with ankylosing spondylitis and its association with inflammation markers. Rheumatol Int 2011; 31(9): 1143-6.
68. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008; 75(3): 291-4.
69. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34(3): 585-92.
70. Sari I, Bozkaya G, Kirbiyik H, et al. Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis. J Rheumatol 2012; 39(3): 594-9.
71. Orüm H, Pamuk GE, Pamuk ON, Demir M, Turgut B. Does anti-TNF therapy cause any change in platelet activation in ankylosing spondylitis patients? A comparative study. J Thromb Thrombolysis 2012; 33(2): 154-9.
72. Jamnitski A, Symmons D, Peters MJ, Sattar N, McIinnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72(2): 211-6.
73. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012; 39(2): 334-6.
74. Pamuk GE, Nuri Pamuk O, Orüm H, Arican O, Turgut B, Demir M. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20(7): 493-7.
75. Canpolat F, Akpinar H, Eskioǧlu F. Mean platelet volume in psoriasis and psoriatic arthritis. Clin Rheumatol 2010; 29(3): 325-8.
76. Lambova SN, Müller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 2009; 29(11): 1263-71.
77. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14(1): 56-63.
78. Giuggioli D, Colaci M, Manfredi A, Mariano M, Ferri C. Platelet gel in the treatment of severe scleroderma skin ulcers. Rheumatol Int 2012; 32(9): 2929-32.
79. Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982; 96(5): 610-3.
80. Friedhoff LT, Seibold JR, Kim HC, Simester KS. Serotonin induced platelet aggregation in systemic sclerosis. Clin Exp Rheumatol 1984; 2(2): 119-23.
81. Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993; 84(4): 675-80.
82. Belch JJ, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol 1985; 24(4): 346-50.
83. Chiang TM, Takayama H, Postlethwaite AE. Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb Res 2006; 117(3): 299-306.
84. Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F, Cervini C. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001; 30(5): 290-6.
85. Solanilla A, Villeneuve J, Auguste P, et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009; 48(9): 1036-44.
86. Kowal-Bielecka O, Kowal K, Lewszuk A, Bodzenta-Lukaszyk A, Walecki J, Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005; 64(3): 484-6.
87. Agache I, Rǎdoi M, Duca L. Platelet activation in patients with systemic scleroderma-pattern and significance. Rom J Intern Med 2007; 45(2): 183-91.
88. Maugeri N, Franchini S, Campana L, et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012; 45(8): 584-7.
89. Ma CY, Jiao YL, Zhang J, et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-β in systemic lupus erythematosus. Rheumatol Int 2012; 32(2): 395-402.
90. Cocco G, Gasparyan AY. Behçet's Disease: an Insight from a Cardiologist's Point of View. Open Cardiovasc Med J 2010; 4: 63-70.
91. Kisacik B, Oren C, Kasifoglu T, et al. Investigation of the veins in patients with Behçet's disease with no known vascular event by Doppler ultrasonography. Rheumatol Int 2012; 32(2): 303-6.
92. Chen KR, Kawahara Y, Miyakawa S, Nishikawa T. Cutaneous vasculitis in Behçet's disease: a clinical and histopathologic study of 20 patients. J Am Acad Dermatol 1997; 36(5 Pt 1): 689-96.
93. Lee JH, Cho SB, Bang D, et al. Human anti-alpha-enolase antibody in sera from patients with Behçet's disease and rheumatologic disorders. Clin Exp Rheumatol 2009; 27(2 Suppl 53): S63-6.
94. La Regina M, Gasparyan AY, Orlandini F, Prisco D. Behçet's Disease as a Model of Venous Thrombosis. Open Cardiovasc Med J 2010; 4: 71-7.
95. Lee YJ, Kang SW, Yang JI, et al. Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res 2002; 106(1): 19-24.
96. Donmez A, Aksu K, Aydin H, et al. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis. Thromb Res 2010; 126(3): 207-10.
97. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11(10): 687-98.
98. Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Livneh A. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36(1): 48-52.
99. Nakano H, Oka H, Matsuda T, et al. Spontaneous platelet aggregation in patients with Behçet's disease by using laser-light scattering aggregometer. Adv Exp Med Biol 2003; 528: 437-41.
100. Wilson AP, Efthimiou J, Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest 1988; 18(4): 410-4.
101. Yapişlar H, Aydogan S, Borlu M, Ascioglu O. Decreased nitric oxide and increased platelet aggregation levels in patients with Behçet's disease. Thromb Res 2007; 119(4): 461-5.
102. Akar S, Ozcan MA, Ateş H, et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost 2006; 12(4): 451-7.
103. Macey M, Hagi-Pavli E, Stewart J, et al. Age, gender and diseaserelated platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet's disease. Rheumatology (Oxford) 2011; 50(10): 1849-59.
104. Tunc SE, Aksu K, Keser G, et al. Platelet-activating factor and Pselectin activities in thrombotic and nonthrombotic Behçet's patients. Rheumatol Int 2005; 25(5): 326-31.
105. Martínez M, Ricart JM, Ruiz-Aja S, et al. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events? Pathophysiol Haemost Thromb 2007; 36(1): 18-22.
106. Pamuk GE, Pamuk ON, Orüm H, Demir M, Turgut B, Cakir N. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study. Blood Coagul Fibrinolysis 2010; 21(2): 113-7.
107. Fernández Bello I, Álvarez MT, López-Longo FJ, et al. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. Thromb Haemost 2012; 107(1): 88-98.
108. Atzeni F, Boiardi L, Nicoli D, et al. PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease. Clin Exp Rheumatol 2011; 29(4 Suppl 67): S38-43.
109. Dogan CS, Akman S, Koyun M, Bilgen T, Comak E, Gokceoglu AU. Prevalence and significance of the MEFV gene mutations in childhood Henoch-Schönlein purpura without FMF symptoms. Rheumatol Int 2013; 33(2): 377-80.
110. Nikibakhsh AA, Houshmand M, Bagheri M, Zadeh HM, Rad IA. MEFV gene mutations (M694V, V726A, M680I, and A744S) in Iranian children with Henoch-Schönlein purpura. Pneumologia 2012; 61(2): 84-7.
111. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21(4 Suppl 30): S35-7.
112. Imirzalioglu N, Dursun A, Tastan B, Soysal Y, Yakicier MC. MEFV gene is a probable susceptibility gene for Behçet's disease. Scand J Rheumatol 2005; 34(1): 56-8.
113. Yazici A, Cefle A, Savli H. The frequency of MEFV gene mutations in Behcet's disease and their relation with clinical findings. Rheumatol Int 2012; 32(10): 3025-30.
114. Esmaeili M, Bonyadi M, Khabbazi A, et al. Common MEFV mutations in Iranian Azeri Turkish patients with Behçet's disease. Scand J Rheumatol 2011; 40(5): 383-6.
115. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21(4 Suppl 30): S35-7.
116. Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets 2008; 19(6): 405-8.
117. Onat AM, Ozçakar L, Oztürk MA, et al. Plasma and platelet serotonin levels in familial Mediterranean fever. Clin Exp Rheumatol 2007; 25(4 Suppl 45): S16-20.
118. Vrij AA, Rijken J, Van Wersch JW, Stockbrügger RW. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest 2000; 30(3): 188-94.
119. Gonzalez-Alegre P, Ruiz-Lopez AD, Abarca-Costalago M, Gonzalez-Santos P. Increment of the platelet count in temporal arteritis: response to therapy and ischemic complications. Eur Neurol 2001; 45(1): 43-5.
120. Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology 2011; 118(6): 1201-4.
121. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372(9634): 234-45.
122. Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. Thrombocytosis in patients with biopsyproven giant cell arteritis. Ophthalmology 2002; 109(7): 1267-71.
123. Maugeri N, Baldini M, Rovere-Querini P, Maseri A, Sabbadini MG, Manfredi AA. Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity 2009; 42(4): 386-8.
124. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50(4): 1332-7.
125. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54(10): 3306-9.
126. Liu R, Gao F, Huo J, Yi Q. Study on the relationship between mean platelet volume and platelet distribution width with coronary artery lesion in children with Kawasaki disease. Platelets 2012; 23(1): 11-6.
127. Guiducci S, Ricci L, Romano E, et al. Microparticles and Kawasaki disease: a marker of vascular damage? Clin Exp Rheumatol 2011; 29(1 Suppl 64): S121-5.
128. Alves NR, Magalhães CM, Almeida Rde F, Santos RC, Gandolfi L, Pratesi R. Prospective study of Kawasaki disease complications: review of 115 cases. Rev Assoc Med Bras 2011; 57(3): 295-300.
129. Rigante D, Valentini P, Rizzo D, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int 2010; 30(6): 841-6.
130. Watanabe T, Kishi Y, Numano F, Isobe M. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. Thromb Res 2001; 104(2): 77-83.
131. Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K. Hypercoagulable state in patients with Takayasu's arteritis. Thromb Haemost 1996; 75(5): 712-6.
132. Kasuya N, Kishi Y, Isobe M, Yoshida M, Numano F. P-selectin expression, but not GPIIb/IIIa activation, is enhanced in the inflammatory stage of Takayasu's arteritis. Circ J 2006; 70(5): 600-4.
133. Bilge NS, Kaşifoǧlu T, Cansu DU, Korkmaz C. Retrospective evaluation of 22 patients with Takayasu's arteritis. Rheumatol Int 2012; 32(5): 1155-9.
134. Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012; 32(3): 703-9.
135. Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012; 125(6): 813-9.
136. Becker-Merok A, Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus 2009; 18(6): 508-15.
137. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012; 18(11): 1543-55.
138. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62(3): 863-8.
139. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87(3): 518-22.
140. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108(9): 1362-70.
141. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996; 15(2): 163-7.
142. Saeed SA, Gilani AH, Rasheed H, et al. Plasma from rheumatoid patients taking low dose methotrexate enhances platelet aggregation. Res Commun Mol Pathol Pharmacol 2002; 111(1-4): 69-76.
143. Goh L, Samanta A. A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 2009; 29(10): 1123-35.
144. Partlett R, Roussou E. The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int 2011; 31(4): 445-9.
145. Farr M, Tunn EJ, Symmons DP, Scott DG, Bacon PA. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 1989; 28(2): 134-8.
146. McKenna KE, Burrows D. Leucopenia, thrombocytopenia and lymphadenopathy associated with sulphasalazine. Clin Exp Dermatol 1994; 19(5): 419-20.
147. Cantarini L, Tinazzi I, Biasi D, Fioravanti A, Galeazzi M. Sulfasalazine-induced immune thrombocytopenia. Postgrad Med J 2007; 83(980): e1.
148. Hopkinson ND, Saiz Garcia F, Gumpel JM. Haematological sideeffects of sulphasalazine in inflammatory arthritis. Br J Rheumatol 1989; 28(5): 414-7.
149. Masuda H, Takahashi Y, Nishida Y, Asai S. Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study. Eur J Clin Pharmacol 2012; 68(11): 1549-55.
150. Stenson WF, Lobos E. Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol 1983; 32(14): 2205-9.
151. Tornhamre S, Edenius C, Smedegård G, Sjöquist B, Lindgren JA. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products. Eur J Pharmacol 1989; 169(2-3): 225-34.
152. Małyszko J, Małyszko JS, Takada A, Myśliwiec M. Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann Transplant 2002; 7(1): 55-68.
153. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32(6): 889-95.
154. Sahin G, Akay OM, Kus E, Bal C, Yalcin AU, Gulbas Z. Effects of immunosuppressive drugs on platelet aggregation and soluble Pselectin levels in renal transplant patients. Ren Fail 2009; 31(2): 111-7.
155. Tarp S, Bartels EM, Bliddal H, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2012; 64(11): 3511-21.
156. Schiff M, Hochberg MC, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 2009; 25(10): 2471-7.
157. Oldenhof J, Hochberg M, Schiff M, Brune K. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. Curr Med Res Opin 2010; 26(6): 1497-504.
158. Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011; 63(3): 850-9.
159. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51(19): 1829-43.
160. Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68(3): 318-23.
161. Freitas DS, Camargo CZ, Mariz HA, Arraes AE, de Souza AW. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012; 32(3): 703-9.
162. de Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010; 74(6): 1236-41.
163. van Buul GM, Koevoet WL, Kops N, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 2011; 39(11): 2362-70.
164. Lippross S, Moeller B, Haas H, et al. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum 2011; 63(11): 3344-53.
165. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013; 41(2): 356-64.
166. Sánchez M, Guadilla J, Fiz N, Andia I. Ultrasound-guided plateletrich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology (Oxford) 2012; 51(1): 144-50.
167. Griffin XL, Wallace D, Parsons N, Costa ML. Platelet rich therapies for long bone healing in adults. Cochrane Database Syst Rev 2012; 7: CD009496.
168. Puente D, Pombo G, Forastiero R. Current management of antiphospholipid syndrome-related thrombosis. Expert Rev Cardiovasc Ther. 2009; 7(12): 1551-8.
169. Shadick NA, Karlson EW, Cook NR, Maher NE, Buring JE, Lee IM. Low-dose aspirin in the primary prevention of rheumatoid arthritis: the Women's Health Study. Arthritis Care Res (Hoboken) 2010; 62(4): 545-50.
170. Abanonu GB, Daskin A, Akdogan MF, Uyar S, Demirtunc R. Mean platelet volume and β-thromboglobulin levels in familial Mediterranean fever: effect of colchicine use? Eur J Intern Med 2012; 23(7): 661-4.
171. Niewold TB, Alpert D, Scanzello CR, Paget SA. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 2006; 33(6): 1194-6.
172. Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus-a prospective pilot study. Rheumatology (Oxford) 2011; 50(9): 1640-4.
173. Alkindi S, Khan S, Riyami D, Farooqi M, Pathare A. Coexistence of immune thrombocytopenic purpura and idiopathic membranous glomerulonephritis successfully treated with rituximab. Platelets 2010; 21(7): 575-7.
174. Suzuki K, Nagasawa H, Kameda H, et al. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48(2): 198-9.
175. Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P. French Network of Pharmacovigilance Centers. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009; 19(4-5): 355-64.